文献速递腹部介入

前路:结直肠癌肝转移的冷冻消融治疗

Path forward: Cryoablation for colorectal liver metastases.
PubMed 文献 · Eur J Radiol · 2026-03-25

CA可为经选择的肝优势、小体积且肝功能保留的患者实现有意义的局部肿瘤控制,但需精准消融并验证切缘,高级别证据仍有限。

要点

  • CA适用于肝优势、小体积、肝功能保留的CRLM患者。
  • CA兼具免疫原性细胞死亡与免疫抑制双重效应。
  • 先进影像与AI定量切缘评估有望预测局部控制。

核心结论

  • CA是CRLM的有价值治疗选择,可实现有意义的局部肿瘤控制。
  • CA机制上诱导免疫原性细胞死亡同时触发免疫抑制通路,尤其中性粒细胞胞外诱捕网形成。
  • CA联合化疗、靶向、免疫检查点抑制剂或手术可能增强抗肿瘤效应,但高级别证据有限。

研究设计与样本

  • 纳入报告肝肿瘤CA临床结局或机制数据的研究,重点为CRLM。
  • 排除肝脏特异性数据不可分离、非肝脏部位、儿科人群及病例数少于5的病例系列。

临床应用与阅片要点

  • 对肝优势、小体积、肝功能保留的CRLM患者可考虑CA。
  • 联合化疗、靶向、免疫检查点抑制剂或手术可能增强疗效。
  • 利用先进影像和人工智能定量评估消融切缘以预测局部控制。

局限性

  • 高级别证据有限。
  • 需精准消融并验证切缘,大病灶及血管旁病灶技术需优化。
  • 需多组学生物标志物指导及多学科肿瘤委员会决策以标准化适应证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Colorectal liver metastases (CRLM) are a leading cause of mortality in patients with colorectal cancer. While surgical resection is the standard curative option, most patients are ineligible. Consequently, cryoablation (CA) has emerged as a potential alternative. This review aims to summarise the technical characteristics, clinical outcomes, immunomodulatory effects, and current combination strategies of CA for CRLM, and to highlight future research directions.

METHODS: This narrative review was informed by a structured literature search in PubMed and Embase (January 2000 - October 2025). Studies reporting clinical outcomes, mechanistic data, or both for CA in hepatic tumours, with a focus on CRLM, were included. Exclusions comprised studies with inseparable liver-specific data, non-hepatic sites, paediatric populations, and case series with fewer than 5 patients.

RESULTS: CA offers a locoregional treatment option that can achieve meaningful local tumour control in carefully selected patients, particularly those with liver-dominant, small-volume disease and preserved liver function. Mechanistically, CA exerts dualistic immunomodulatory effects: while it induces immunogenic cell death, it simultaneously triggers immunosuppressive pathways, in particular neutrophil extracellular trap formation. Accumulating evidence suggests that combining CA with chemotherapy, targeted agents, immune checkpoint inhibitors, or surgical resection may enhance anti-tumour effects, although high-level evidence remains limited. Notably, quantitative margin assessment using advanced imaging and artificial intelligence is emerging as a promising tool for predicting local control and optimising outcomes.

CONCLUSION: CA serves as a valuable therapeutic option for CRLM. Broader clinical application requires precision ablation with verified margins, technical optimisation for larger and perivascular lesions, biomarker-guided strategies supported by multi-omics, and robust multidisciplinary tumour board decision-making to standardise indications.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Li G, Zhu B, Li J, et al. Path forward: Cryoablation for colorectal liver metastases. Eur J Radiol. 2026. PMID: 41926877. doi:10.1016/j.ejrad.2026.112817

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。